Anti-HIV Agents - Administration & dosage
Research News and Information

Monday, November 23, 2009

Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression.

30 Oct 2009 BACKGROUND: Achieving virologic suppression is a clear therapeutic goal for patients receiving combination antiretroviral therapy (cART). However, the effects of immunologic responses, whether measured as CD4 count changes from baseline or CD4 ... Read more...

Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection.

30 Oct 2009 BACKGROUND: Boosted darunavir (DRV/r) plus etravirine (ETR), in DUET trials, and raltegravir, in BENCHMRK trials, showed high rates of virologic response in patients with multidrug-resistant HIV-1 infection, particularly when associated with two ... Read more...

Gender differences in discontinuation of antiretroviral treatment regimens.

30 Oct 2009 BACKGROUND: Reported reasons for change or discontinuation of antiretroviral therapy ([delta]ART) include adverse events, intolerability, and nonadherence. Little is known how reasons for [delta]ART differ by gender. METHODS: In a retrospective ... Read more...

Latest indexed articles for 'Anti-HIV Agents - Administration & dosage'

These are the very latest articles for this heading:

• Nanotechnology for antiretroviral drug delivery. 29 Nov 2009
• Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression. 30 Oct 2009
• Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection. 30 Oct 2009
• Gender differences in discontinuation of antiretroviral treatment regimens. 30 Oct 2009
• Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. 30 Oct 2009
• Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting. 30 Oct 2009
• Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells. 13 Oct 2009
• Antiretroviral adherence and pharmacokinetics: review of their roles in sustained virologic suppression. 29 Sep 2009
• Immunogenicity and immunologic memory after hepatitis B virus booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. 13 Sep 2009
• Efficacy and safety of atazanavir-ritonavir plus abacavir-lamivudine or tenofovir-emtricitabine in patients with hyperlipidaemia switched from a stable protease inhibitor-based regimen including one thymidine analogue. 30 Aug 2009
• Queaze, sneeze, yawn, and runs. A little laundry list of possible side effects of the different HIV drug classes. 30 Aug 2009
• New technologies promise safer sex for women. 30 Aug 2009
• Mortality and virologic outcomes after access to antiretroviral therapy among a cohort of HIV-infected women who received single-dose nevirapine in Lusaka, Zambia. 30 Aug 2009
• Proteinuria, creatinine clearance, and immune activation in antiretroviral-naive HIV-infected subjects. 13 Aug 2009
• A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals. 13 Aug 2009
• Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. 13 Aug 2009
• Lower risk of resistance after short-course HAART compared with zidovudine/single-dose nevirapine used for prevention of HIV-1 mother-to-child transmission. 13 Aug 2009
• Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. 3 Aug 2009
• Modeling comparative effectiveness and the value of research. 2 Aug 2009
• Targeting anti-HIV drugs to the CNS. 30 Jul 2009

See a longer list of these articles.

Technical information about 'Anti-HIV Agents'

Definition: Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS.

Registry Number: 0

Descriptor UI: D019380

Alternative terms: Anti-HIV Agents; Agents, Anti-HIV; Anti HIV Agents; Anti-HIV Drugs; Anti HIV Drugs; Drugs, Anti-HIV; AIDS Drugs; Drugs, AIDS; Anti-AIDS Agents; Agents, Anti-AIDS; Anti AIDS Agents; Anti-AIDS Drugs; Anti AIDS Drugs; Drugs, Anti-AIDS;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D27.505.954.122.388.077.088;

History Note: 97

Technical Notes: consider also AIDS /drug ther; may be used for articles on simian acquired immunodefic syndrome & simian immunodefic virus